SE441753B - Sett att framstella en skyddad polypeptid med minskad benegenhet till immunicering och bibehallen fysiologisk aktivitet - Google Patents

Sett att framstella en skyddad polypeptid med minskad benegenhet till immunicering och bibehallen fysiologisk aktivitet

Info

Publication number
SE441753B
SE441753B SE7409366A SE7409366A SE441753B SE 441753 B SE441753 B SE 441753B SE 7409366 A SE7409366 A SE 7409366A SE 7409366 A SE7409366 A SE 7409366A SE 441753 B SE441753 B SE 441753B
Authority
SE
Sweden
Prior art keywords
physiological activity
polypeptime
immunization
diminished
prone
Prior art date
Application number
SE7409366A
Other languages
English (en)
Swedish (sv)
Other versions
SE7409366L (2
Inventor
F F Davis
Es T Van
N C Palczuk
Original Assignee
Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp filed Critical Research Corp
Publication of SE7409366L publication Critical patent/SE7409366L/xx
Publication of SE441753B publication Critical patent/SE441753B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)
SE7409366A 1973-07-20 1974-07-18 Sett att framstella en skyddad polypeptid med minskad benegenhet till immunicering och bibehallen fysiologisk aktivitet SE441753B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38119173A 1973-07-20 1973-07-20

Publications (2)

Publication Number Publication Date
SE7409366L SE7409366L (2) 1975-01-21
SE441753B true SE441753B (sv) 1985-11-04

Family

ID=23504063

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7409366A SE441753B (sv) 1973-07-20 1974-07-18 Sett att framstella en skyddad polypeptid med minskad benegenhet till immunicering och bibehallen fysiologisk aktivitet

Country Status (9)

Country Link
JP (1) JPS5623587B2 (2)
CA (1) CA1033673A (2)
CH (1) CH616942A5 (2)
DE (1) DE2433883C2 (2)
FR (1) FR2313939A1 (2)
GB (1) GB1469472A (2)
IL (1) IL45291A0 (2)
NL (1) NL7409770A (2)
SE (1) SE441753B (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930542A1 (de) * 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
WO1985003934A1 (fr) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
JPS59204130A (ja) * 1983-04-30 1984-11-19 Nippon Chemiphar Co Ltd 新規プラスミノ−ゲンアクチベ−タ誘導体を含有してなる経口投与薬剤
DE3334407A1 (de) * 1983-09-23 1985-04-04 Hoechst Ag, 6230 Frankfurt In position b 30 modifizierte insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
JPS61163687U (2) * 1985-03-28 1986-10-09
JPS62207485A (ja) * 1986-03-07 1987-09-11 大平技研工業株式会社 テレビゲ−ム機
US5037969A (en) * 1986-07-03 1991-08-06 Takeda Chemical Industries, Ltd. Glycosyl derivatives and use thereof
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5578496A (en) * 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
AU3423293A (en) * 1991-12-19 1993-07-19 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
EP1438073B1 (en) * 1999-09-10 2010-08-11 The Procter & Gamble Company Polyoxyalkylene conjugates as enzyme inhibitors
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
CN105131104B (zh) * 2001-10-10 2018-11-16 诺和诺德公司 肽的重构和糖缀合
PT1436012T (pt) * 2001-10-18 2018-03-27 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
EP1494706A4 (en) * 2002-03-26 2006-10-25 Biosynexus Inc ANTIMICROBIAL POLYMER CONJUGATES
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
JP5030383B2 (ja) * 2002-10-21 2012-09-19 アルヴィヴォ インコーポレイテッド 生物活性化合物を含む表面コーティング
US7498415B2 (en) 2003-09-24 2009-03-03 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
US7790835B2 (en) 2003-12-03 2010-09-07 Nektar Therapeutics Method of preparing maleimide functionalized polymers
EP1893240A2 (en) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
US7301003B2 (en) * 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US10046058B2 (en) * 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
US20170342211A1 (en) * 2016-05-31 2017-11-30 Robert Bosch Gmbh Azlactone functionalized substrates for conjugation of biomolecules
HUE057856T2 (hu) * 2016-06-01 2022-06-28 Servier Ip Uk Ltd Polialkilén-oxid-aszparagináz készítményei és eljárás ezek elõállítására és alkalmazására

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (2) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
US3674767A (en) * 1967-07-14 1972-07-04 Nat Res Dev Novel polymeric materials containing triazinyl groups

Also Published As

Publication number Publication date
SE7409366L (2) 1975-01-21
DE2433883C2 (de) 1986-03-27
NL7409770A (nl) 1975-01-22
CA1033673A (en) 1978-06-27
GB1469472A (en) 1977-04-06
FR2313939A1 (fr) 1977-01-07
DE2433883A1 (de) 1976-02-05
JPS5042087A (2) 1975-04-16
JPS5623587B2 (2) 1981-06-01
CH616942A5 (en) 1980-04-30
FR2313939B1 (2) 1979-05-18
IL45291A0 (en) 1974-10-22

Similar Documents

Publication Publication Date Title
SE441753B (sv) Sett att framstella en skyddad polypeptid med minskad benegenhet till immunicering och bibehallen fysiologisk aktivitet
ES8103171A1 (es) Un procedimiento de preparacion de monacolina k.
JPS51139842A (en) Stabilizer for synthetic polymeric material
JPS5259644A (en) Stabilizer for polymer
ATE107280T1 (de) Carbamoyl-2-pyrrolidinonverbindungen.
ES441678A1 (es) Un procedimiento de obtencion de nuevas composiciones poli- meras.
ATE22011T1 (de) Virusimpfstoffe und verfahren zu ihrer herstellung.
EP0529019A4 (en) Nematode vaccine
ES414955A1 (es) Procedimiento para la preparacion de 4-(4-bifenilil)-buta- noles.
ES472276A1 (es) Un procedimiento para la preparacion de un grupo de cis-4a- aril-octahidro-1h-2-pirindinas 2-sustituidas
ES390778A1 (es) Un procedimiento para la fabricacion de fenilaminoalcanos.
ES407358A1 (es) Metodo para la preparacion de esteres y tiolesteres alifa- ticos.
JPS5518409A (en) Preparation of polyurethane elastomer
FR2425429A1 (fr) N-cyano-azomethines utilisables pour la preparation d'antihistaminiques et leur preparation
SE7613536L (sv) Sett att framstella 3,4-disubstituerade 2-(beta-naftyl-oxi)-etylpyrazoloner och anvendning derav som lekemedel
ES394637A1 (es) Procedimiento para estabilizar material organico posible dedegradacion oxidatica o termica.
JPS5340719A (en) Organophosphorus compound and chlorine-containing resin composition
JPS55154918A (en) Carcinostatic
SU593451A1 (ru) Способ стабилизации бутилкаучука
SU701101A1 (ru) Производные 2-х-бензилиденгидразино-4-фенил-5n-r- сульфамоилфенилазотиазола, обладающие акарицидной активностью
ES457416A1 (es) Un procedimiento para la preparacion de poli(tetrametilen- eter)glicol.
ES420004A1 (es) Un procedimiento para la preparacion de un derivado de ni- trosourea.
ES289006A1 (es) Procedimiento para la preparación de polímeros estabilizados
ES403328A1 (es) Procedimiento para la preparacion de derivados de biciclo- alcano.
JPS53147059A (en) Brominated cyclic ether having alkoxycarbonyl group and its preparation

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 7409366-7

Effective date: 19940810

Format of ref document f/p: F